Press Releases

Date Title
Toggle Summary Aeglea BioTherapeutics to Participate in Upcoming Investor Conferences
AUSTIN, Texas , Nov. 26, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide solutions for diseases with unmet medical need, today announced that Anthony G. Quinn , M.B.
Toggle Summary Aeglea BioTherapeutics Reports Third Quarter 2019 Financial Results and Corporate Highlights
AUSTIN, Texas , Nov. 06, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide solutions for diseases with unmet medical need, today reported financial results for the third quarter ended
Toggle Summary Aeglea BioTherapeutics Strengthens Leadership Team with Appointment of Ravi M. Rao as Chief Medical Officer and Michael C. Hanley as Chief Commercial Officer
AUSTIN, Texas , Nov. 04, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide solutions for diseases with unmet medical need, today announced two additions to its senior management team.
Toggle Summary Aeglea BioTherapeutics to Present at 21st Annual H.C. Wainwright Global Investment Conference
Live Webcast Scheduled for 5:30 p.m. ET on Monday, September 9 AUSTIN, Texas , Sept. 05, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide solutions for diseases with unmet medical
Toggle Summary Aeglea BioTherapeutics Announces Positive 20-Dose Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 2019 SSIEM Symposium
Sustained Control of Plasma Arginine Accompanied by Clinical Response; Overall Clinical Responder Rate of 79% Management to Host Conference Call at 9:00 a.m. ET on Tuesday, September 3 AUSTIN, Texas , Sept. 03, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc.
Toggle Summary Aeglea BioTherapeutics to Present New 20-Dose Data for Pegzilarginase in Patients with Arginase 1 Deficiency at 2019 SSIEM Symposium
Management to Host Conference Call at 9:00 a.m. ET on Tuesday, September 3 AUSTIN, Texas , Aug. 29, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide solutions for diseases with unmet
Toggle Summary Aeglea BioTherapeutics Reports Second Quarter 2019 Financial Results and Corporate Highlights
FDA Breakthrough Therapy Designation Received for Pegzilarginase in Treatment of Arginase 1 Deficiency Dosed First Patient in Global Pivotal Phase 3 PEACE Trial New Data from Arginase 1 Deficiency Phase 2 Extension Trial Expected in September 2019 AUSTIN, Texas , Aug.
Toggle Summary Aeglea BioTherapeutics Receives FDA Breakthrough Therapy Designation for Pegzilarginase for Treatment of Arginase 1 Deficiency
Designation Follows Recently Reported ARG1-D Phase 1/2 Data Demonstrating Clinical Response in Patients Treated with Pegzilarginase AUSTIN, Texas , July 24, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company that engineers next-generation
Toggle Summary Aeglea BioTherapeutics Doses First Patient in Pivotal Phase 3 PEACE Trial of Pegzilarginase in Arginase 1 Deficiency
Topline Data from PEACE Anticipated in First Quarter of 2021 New Data from ARG1-D Phase 1/2 Extension Study Expected in September 2019 AUSTIN, Texas , June 03, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company that engineers next-generation
Toggle Summary Aeglea BioTherapeutics to Participate in Upcoming Investor and Industry Conferences
AUSTIN, Texas , May 30, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide solutions for diseases with unmet medical need, today announced that Anthony G. Quinn , M.B.
Toggle Summary Aeglea BioTherapeutics Reports First Quarter 2019 Financial Results and Corporate Highlights
Statistically Significant Reductions in Plasma Arginine with Accompanying Clinical Improvements with Pegzilarginase in Phase 1/2 Reaffirm Pivotal Trial Design Gross Proceeds of $69 Million from February 2019 Public Offering Extends Cash Runway Through Q1 of 2021 Pivotal Phase 3 Trial of
Toggle Summary Aeglea BioTherapeutics Announces New Positive Phase 1/2 Data for Pegzilarginase in Patients with Arginase 1 Deficiency at 2019 Annual Meeting of the Society for Inherited Metabolic Disorders
Consistent, Marked, and Sustained Lowering of Elevated Plasma Arginine with Pegzilarginase Clinically Impactful Responses Captured by Mobility and Adaptive Behavior Assessments Management to Host Conference Call at 8:30 a.m. ET on Monday, April 8 AUSTIN, Texas , April 07, 2019 (GLOBE NEWSWIRE) --
Toggle Summary Aeglea BioTherapeutics to Present Updated Phase 1/2 Data for Pegzilarginase in Patients with Arginase 1 Deficiency in an Oral Presentation at the 2019 Annual Meeting of the Society for Inherited Metabolic Disorders
Management to Host Conference Call at 8:30 a.m. ET on Monday, April 8 AUSTIN, Texas , April 01, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic
Toggle Summary Aeglea BioTherapeutics to Participate in Upcoming Investor Conferences
AUSTIN, Texas , March 28, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced that Anthony G. Quinn , M.B.
Toggle Summary Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Corporate Highlights
On Track to Dose First Patient in Pivotal Phase 3 Trial of Pegzilarginase for ARG1-D in Q2 of 2019 Initiated IND-Enabling Studies for New Pipeline Programs Progress with Pegzilarginase Cancer Indication-Phase 2 Combination Study Initiated Gross Proceeds of $69 Million from February 2019 Public